Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
---|
06/28/2012 | US20120164227 New granulating process and thus prepared granulate |
06/28/2012 | US20120164226 Compositions and Methods for Improving Prognosis of a Human with Subarachnoid Hemorrhage |
06/28/2012 | US20120164222 Novel compounds and compositions and methods of use |
06/28/2012 | US20120164221 Combinations of hmg-coa reductase inhibitors and nicotinic acid compounds and methods for treating hyperlipidemia once a day at night |
06/28/2012 | US20120164220 Encased Tamper Resistant Controlled Release Dosage Forms |
06/28/2012 | US20120164218 Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same |
06/28/2012 | US20120164216 Pharmaceutical composition of duloxetine or pharmaceutically |
06/28/2012 | US20120164215 Topical co-enzyme q10 formulations and methods of use |
06/28/2012 | US20120164213 Time-release and micro-dose formulations for topical application of estrogen and estrogen analogs or other estrogen receptor modulators in the treatment of dry eye syndrome, and methods of preparation and application |
06/28/2012 | US20120164211 Compositions and methods for treating lymphoma |
06/28/2012 | US20120164210 Photodynamic therapeutic agent having cell-specific active accumulation properties |
06/28/2012 | US20120164209 Abuse resistant drugs, method of use and method of making |
06/28/2012 | US20120164208 Chitosan hydrogel derivatives as a coating agent with broad spectrum of antimicrobial activities |
06/28/2012 | US20120164207 Degradable networks for sustained release and controlled release depot drug delivery applications |
06/28/2012 | US20120164193 Extended-release formulation for reducing the frequency of urination and method of use thereof |
06/28/2012 | US20120164192 Delayed release formulation for reducing the frequency of urination and method of use thereof |
06/28/2012 | US20120164191 Transmucosal delivery devices with enhanced uptake |
06/28/2012 | US20120164190 Nanoparticle isoflavone compositions & methods of making and using the same |
06/28/2012 | US20120164188 Paliperidone or a pharmaceutically acceptable salt thereof substantially free of impurities |
06/28/2012 | US20120164183 Method for detection and treatment of aneurysms |
06/28/2012 | US20120164171 Antiviral Activity of Bovine Type III Interferon Against Foot-and-Mouth Disease Virus |
06/28/2012 | US20120164154 Method for increasing insulin sensitivity and for treating and preventing type 2 diabetes |
06/28/2012 | US20120164151 Methods for Treatment of Muscular Dystrophy |
06/28/2012 | US20120164149 Use of inhibitors of leukotriene b4 receptor blt2 for treating asthma |
06/28/2012 | US20120164148 Compositions Containing JARID1B Inhibitors and Methods for Treating Cancer |
06/28/2012 | US20120164145 H. pylori lipopolysaccharide outer core epitope |
06/28/2012 | US20120164142 Compositions comprising natriuretic peptides and methods of use thereof |
06/28/2012 | US20120164139 Dopamine 3 receptor agonist and antagonist treatment of gastrointestinal motility disorders |
06/28/2012 | US20120164136 Compositions and Methods for Treatment of Cancer by Disrupting the LH/LHR Signaling Pathway |
06/28/2012 | US20120164134 Sugar-free chewable supplement |
06/28/2012 | US20120164128 Means and methods for counteracting polyq expansion disorders |
06/28/2012 | US20120164124 Phage-associated lytic enzymes for treatment of bacillus anthracis and related conditions |
06/28/2012 | US20120164122 Phytoestrogenic formulations for alleviation or prevention of neurodegenerative diseases |
06/28/2012 | US20120164120 Novel monascuspurpurones, preparation process thereof, and uses of the monascuspurpurones |
06/28/2012 | US20120164108 Virus strains |
06/28/2012 | US20120164104 Composition and Methods of Treating Viral Infections and Viral Induced Tumors |
06/28/2012 | US20120164103 Compounds and Methods for the Treatment or Prevention of Flavivirus Infections |
06/28/2012 | US20120164102 Salts of bicyclo-substituted pyrazolon azo derivatives, preparation method and use thereof |
06/28/2012 | US20120164101 Gm-csf and interleukin-21 conjugates and uses thereof in the modulation of immune response and treatment of cancer |
06/28/2012 | US20120164080 Methods of treatment for esophageal inflammation |
06/28/2012 | US20120164078 Methods of using sustained release aminopyridine compositions |
06/28/2012 | US20120164076 Methods of treatment using thymus-derived compositions |
06/28/2012 | US20120164075 Endoxifen methods and compositions in the treatment of mammalian diseases |
06/28/2012 | US20120164074 Methods of diagnosing, preventing and treating cancer metastasis |
06/28/2012 | US20120164072 Nano-sized particles comprising multi-headed amphiphiles for targeted drug delivery |
06/28/2012 | US20120164070 Benzothiazole and benzooxazole derivatives and methods of use |
06/28/2012 | US20120164067 Methods of preventing or treating pain using anti-ngf antibodies that selectively inhibit the association of ngf with trka, without affecting the association of ngf with p75 |
06/28/2012 | US20120164065 Method and composition for treating cancer |
06/28/2012 | DE102010064245A1 Use of macrocyclic lactones used in controlling endoparasitic filariae and gastrointestinal nematodes, particularly used in controlling heartworm |
06/28/2012 | DE102010063974A1 Preparing a radioactive fluorine substituted (1,2,4)oxadiazole compound, useful as radiodiagnostic to diagonize e.g. neurological and psychiatric disorders, comprises reacting a (1,2,4)oxadiazole compound with a radioactive fluorine |
06/28/2012 | DE102010056443A1 New chlorin derivative useful as photosensitizer in photodynamic tumor therapy |
06/28/2012 | DE102010055771A1 Composition useful as a medicament for therapeutic, prophylactic, cosmetic or health-promoting functions in e.g. humans comprises chlorite and polyvalent alcohol in aqueous or alcoholic-aqueous chlorine dioxide-containing solution |
06/28/2012 | CA2845524A1 Substituted methyl amines, serotonin 5-ht6 receptor antagonists, methods for the production and use thereof |
06/28/2012 | CA2822923A1 A process for the preparation of lapatinib and its ditosylate salt |
06/28/2012 | CA2822898A1 Compositions and methods for improving mitochondrial function and treating neurodenegenerative diseases and cognitive disorders |
06/28/2012 | CA2822842A1 Faah inhibitors |
06/28/2012 | CA2822805A1 Novel imidazole-2-benzamide compounds useful for the treatment of osteoarthritis |
06/28/2012 | CA2822795A1 Novel preparation of an enteric release system |
06/28/2012 | CA2822790A1 Encased tamper resistant controlled release dosage forms |
06/28/2012 | CA2822789A1 Substituted pyridines as sodium channel blockers |
06/28/2012 | CA2822787A1 Novel substituted isoquinoline derivative |
06/28/2012 | CA2822769A1 Tamper resistant solid oral dosage forms |
06/28/2012 | CA2822767A1 Polymorphs of 3-chloro-4[(2r)-2-(4-chlorophenyl)-4-[(1r)-1-(4-cyanophenyl)ethyl]-1-piperazinyl]-benzonitrile, pharmaceutical compositions and method of use comprising said polymorphs, and a process for preparing them |
06/28/2012 | CA2822758A1 Optically active diazabicyclooctane derivative and process for preparing the same |
06/28/2012 | CA2822745A1 A composition comprising at least to compounds which induces indolamine 2,3-dioxygenase (ido), for the treatment of an autoimmune disorder or suffering from immune rejection of organs |
06/28/2012 | CA2822725A1 Modulators and methods for the treatment of rosacea |
06/28/2012 | CA2822701A1 Novel pharmaceutical composition |
06/28/2012 | CA2822694A1 Purified cardiogenin isomer and related methods |
06/28/2012 | CA2822672A1 Methods for treating copd |
06/28/2012 | CA2822639A1 Methods for treating systemic lupus erythematosus using hiv protease inhibitors |
06/28/2012 | CA2822617A1 Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides |
06/28/2012 | CA2822565A1 Bi-heteroaryl compounds as vps34 inhibitors |
06/28/2012 | CA2822553A1 Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
06/28/2012 | CA2822547A1 Dermatological foams obtained from a gel or suspension containing benzoyl peroxide |
06/28/2012 | CA2822546A1 Dermatological foams obtained from a gel or suspension containing adapalene |
06/28/2012 | CA2822539A1 Dermatological foams obtained from a gel or suspension containing a combination of adapalene and benzoyl peroxide |
06/28/2012 | CA2822493A1 Selective glycosidase inhibitors and uses thereof |
06/28/2012 | CA2822453A1 Novel morphinans useful as analgesics |
06/28/2012 | CA2822432A1 Bicyclic pkm2 activators |
06/28/2012 | CA2822410A1 Novel platinum-carbene complexes and use thereof as medicaments |
06/28/2012 | CA2822378A1 Compounds and their use as bace inhibitors |
06/28/2012 | CA2822360A1 Ingenol-3-acylates i |
06/28/2012 | CA2822357A1 Hepatitis c inhibitors and uses thereof |
06/28/2012 | CA2822347A1 Sanglifehrin derivatives and methods for their production |
06/28/2012 | CA2822320A1 Composition for the treatment of skin conditions |
06/28/2012 | CA2822312A1 3-acyl-ingenols ii |
06/28/2012 | CA2822310A1 Ingenol-3-acylates iii and ingenol-3-carbamates |
06/28/2012 | CA2822265A1 Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient |
06/28/2012 | CA2822263A1 Methods and compositions for preventing and treating osteoarthritis |
06/28/2012 | CA2822213A1 Combination and composition for treating obesity |
06/28/2012 | CA2822166A1 Indazolyl triazole derivatives as irak inhibitors |
06/28/2012 | CA2822080A1 Ectoparasiticidal active substance combinations |
06/28/2012 | CA2822070A1 N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors |
06/28/2012 | CA2822037A1 Methods for treating hcv |
06/28/2012 | CA2822027A1 Halogenated biphenols as antibacterial agents |
06/28/2012 | CA2822017A1 Glucagon receptor modulators |
06/28/2012 | CA2821937A1 Bicyclo[3.2.1]octyl amide derivatives and uses of same |
06/28/2012 | CA2821807A1 Methods and compositions suitable for managing blood glucose in animals |
06/28/2012 | CA2821638A1 Conjugated 3-(indolyl)- and 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment |
06/28/2012 | CA2821546A1 2-arylimidazo[1,2-b]pyridazine, 2-phenylimidazo[1,2-a]pyridine, and 2-phenylimidazo[1,2-a]pyrazine derivatives |